Article citationsMore>>

Gridelli, C., Gallo, C., Shepherd, F.A., Illiano, A., Piantedosi, F., Robbiati, S.F., Manzione, L., Barbera, S., Frontini, L., Veltri, E., Findlay, B., Cigolari, S., Myers, R., Ianniello, G.P., Gebbia, V., Gasparini, G., Fava, S., Hirsh, V., Bezjak, A., Seymour, L. and Perrone, F. (2003) Gemcitabine plus Vinorelbine Compared with Cisplatin plus Vinorelbine or Cisplatin plus Gemcitabine for Advanced Non-Small-Cell Lung Cancer: A Phase III Trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology, 21, 3025-3034.
https://doi.org/10.1200/jco.2003.06.099

has been cited by the following article:

• TITLE: Patient-Reported Outcomes of Chemotherapy Involving Non-Small Cell Lung Cancer: Evaluation by Questionnaires of Quality of Life Regarding Anti-Aging and Anti-Cancer Drugs

  AUTHORS: Takanori Ayabe, Masaki Tomita, Takashi Asada, Kazuyo Tsuchiya, Manabu Nemoto, Kunihide Nakamura

  KEYWORDS: Patient-Reported Outcome, Chemotherapy, Quality of Life, Non-Small Cell Lung Cancer

  JOURNAL NAME: Advances in Lung Cancer, Vol.6 No.2, June 22, 2017

  ABSTRACT: Background: Patient-reported outcomes (PROs) of quality of life (QOL) during chemotherapy involving lung cancer are very important for the medical staffs. Patients’ satisfaction and healthy changes were evaluated by the patient-self assessment. Materials and Methods: From July 2007 to April 2008, a total of 19 patients received chemotherapy. The QOL data were collected by using the QOL questionnaire for cancer patients treated with anticancer drugs (QOL-ACD) and the anti-aging QOL assessment (AA-QOL). The AA-QOL contained 51 items: 30 of physical and 21 of mental symptoms of the elderly and the aging population. The patients replied to the questions at two different times, i.e., at pre-chemotherapy (baseline) and at post-chemotherapy (2 weeks after the chemotherapy). Results: Regarding the hematological toxicities, for the grade 3/4 toxicities, there were 12 neutropenia (12/19, 63.2%) and 3 thrombocytopenia (3/19, 15.8%). For the grade 3 febrile neutropenia, there were 5 cases (5/19, 26.3%). Regarding the non-hematological toxicities, there was no grade 3 and grade 4 toxicities. Based on the outcomes of the QOL-ACD, the three items (“physical condition”, “social attitude”, and “overall QOL”) at post-chemotherapy became significantly worse compared to the baseline. Regarding the outcomes of the AA-QOL, 4 items of physical symptoms (“thirst”, “anorexia”, “early satiety”, and “diarrhea”) became significantly worse compared to the baseline. Regarding the mental symptoms, 2 items (“nothing to look forward in life” and “a sense of uselessness”) became significantly worse compared to the baseline. Conclusion: Regarding the PROs of the QOL during the chemotherapy term, both the physical and mental symptoms had become worse. To clarify the changes in the QOL during chemotherapy is very important for multidisciplinary teamwork, which should play the role of providing the appropriate cares and treatment as patient-support.